CBD Improved Memory and Reduced Alzheimer's Markers in Mouse Model

In the 5xFAD Alzheimer's mouse model, CBD decreased pTau and amyloid-beta aggregation, reduced their transport between brain regions, shifted microglia toward a neuroprotective M2 phenotype, reduced inflammatory cytokine release, and partially reversed neurite formation loss. Daily CBD injections (10 mg/kg for 28 days) significantly improved both short- and long-term spatial memory. CBD also reduced reactive oxygen species and increased neuronal survival.

Combined in vitro and in vivo study using the 5xFAD Alzheimer's mouse model. In vitro: assessed CBD effects on protein aggregation, axonal transport, microglial polarization, neurite formation, and oxidative stress. In vivo: daily CBD injections (10 mg/kg) for 28 days with subsequent spatial memory testing.

Most Alzheimer's drugs target a single disease mechanism, but CBD addressed multiple pathological processes simultaneously: amyloid plaques, tau tangles, neuroinflammation, oxidative stress, and neuronal damage. This multi-target approach is increasingly recognized as necessary for complex neurodegenerative diseases.

The failure rate for Alzheimer's drugs has been extremely high, partly because the disease involves multiple interacting pathological processes. CBD's ability to simultaneously target several of these processes in an animal model makes it an interesting candidate, though the gap between mouse models and human Alzheimer's disease remains substantial.

Mouse model (5xFAD) does not fully replicate human Alzheimer's disease. CBD was injected, not given orally. Single dose level tested. 28-day treatment period is short relative to the chronic nature of Alzheimer's. Cannot predict human pharmacokinetics or required doses.